French Debt Crisis Sparks Concern in Tokyo and Beyond

France is facing a growing debt crisis, with rising bond yields causing investors to view Paris as a riskier prospect than previously thought, even more so than Italy, once considered the Eurozone's weak link. France's public debt has reached approximately 119% of its GDP, and market concerns are mounting over a combination of high deficits, political instability, and upcoming elections potentially widening the spread against German bonds.

This situation is drawing the attention of Japanese investors, who are significant players in global markets with over $10 trillion in foreign holdings. For years, they have provided stable demand for government bonds worldwide, including in France, where they hold a substantial portion of the debt. However, they are now shifting their strategy, selling foreign bonds and reallocating funds to stocks, safer German bonds, and short-term Japanese bonds. Some funds have even divested entirely from French bonds.

France's reliance on foreign investment is significant, with over half of its government debt held internationally. The decision by Japanese investors, who can achieve around 3% yield domestically with lower risk, to reduce their exposure to France is increasing pressure on the French market. This shift, originating from a major global capital source, is exacerbating the crisis of confidence in French debt.

If Japan, a key global capital provider, begins to favor repatriating funds or investing in safer assets, other European nations could also find their debt financing becoming more expensive and uncertain. In an era of rising yields and increasing skepticism towards traditionally safe assets, Europe can no longer assume a continuous flow of Japanese capital.

In a separate development, Israel's Ministry of Health is facing criticism regarding a reform aimed at improving services for children with developmental disabilities. Despite a budget of 100 million shekels allocated for the reform, Director General Moshe Bar Siman Tov stated that waiting time data is not relevant for assessing its success and expressed no realistic expectation of reduced waiting times. This stance contradicts earlier commitments and has drawn criticism from Knesset members who question how the reform's effectiveness can be measured without proper metrics. The reform aimed to address long waiting lists, sometimes exceeding a year, for treatments for conditions like autism and cerebral palsy. The ministry's shift in approach has led to calls for clarification from parliamentary leaders.